



(43) International Publication Date
30 May 2014 (30.05.2014)

(10) International Publication Number
WO 2014/081732 A1

(51) International Patent Classification:

A61K 31/407 (2006.01) *C07D 487/04* (2006.01)
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2013/070834

(22) International Filing Date:

19 November 2013 (19.11.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/728,539 20 November 2012 (20.11.2012) US

(71) Applicant: **PRINCIPIA BIOPHARMA INC.** [US/US];
400 East Jamie Court, Suite 302, South San Francisco, CA
94080 (US).

(72) Inventors: **GOLDSTEIN, David, Michael**; 122 Danbury
Lane, Redwood City, CA 94061 (US). **BRAMELD, Ken-
neth, Albert**; 345 Camino Al Lago, Menlo Park, CA
94027 (US). **OWENS, Tim**; 5 Pyxie Ln, San Carlos, CA
94070 (US).

(74) Agent: **RODRIGO, Christina, M.**; Finnegan, Henderson,
Farabow, Garrett & Dunner, LLP, 901 New York Avenue
NW, Washington, DC, DC 20001-4413 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS

(57) Abstract: The present disclosure provides compounds that are JAK3 inhibitors and therefore useful for the treatment of dis-
eases treatable by inhibition of JAK3 such as cancer and inflammatory diseases. Also provided are pharmaceutical compositions
containing such compounds and processes for preparing such compounds.



WO 2014/081732 A1